Curtis Lachowiez
0000-0001-8506-0624
2 papers found
Refreshing results…
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
Missing publications? Search for publications with a matching author name.